Insider trade

Director sold ~$358K of HALO shares in the open market

Traded Oct 1, 2026 · Filed Oct 2, 2026

HalozymeHALO

~$358K
Reported value · 3,300 sh @ $108.45: 55K
Holds after · shares reported: +1.3%
stock since the trade · S&P 500 +1.4%, $106.94 → $108.31 on Oct 5

Why it stands out

A board member of Halozyme sold $358K of Halozyme shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Oct 1, 2026
Reporting period: Not applicable
Filed with the SEC: Oct 2, 2026

Director$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$357,898

Shares × reported transaction price

Timing vs results

56 days after results of Aug 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $106.94 on Oct 1, 2026, 74% above its 52-week low and 7% below its high, little changed over the previous 30 trading days

52-week range $61.63 (Mar 27, 2026) to $115.22 (Sep 24, 2026), 85% of the way up, from 249 adjusted closes. 30 trading days earlier: $107.62 on Aug 19, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001159036-26-000133
Filed / recorded: Oct 2, 2026, 8:38 PM UTC
Added to OQRO: Oct 6, 2026, 7:59 PM UTC
Parser: form4-xml-v2
Data quality: Verified: identifiers matched exactly
Issuer: HALOZYME THERAPEUTICS, INC.
Issuer CIK: 1159036
Ticker: HALO
Reporting person: Matthew L. Posard
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Oct 1, 2026
Transaction code: S
Shares / units: 3,300
Price per share: $108.45
Acquired / disposed: Disposed (D)
Shares owned after: 54,809
Ownership form: Direct
Amendment: No

Footnotes from the filing

The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.
Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.990 to $108.930. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Around the same time

1,169Shares

5d ago

Compensation award — excluded from discretionary-purchase analysis.

More Official record

1,775Derivative units

5d ago

Compensation award — excluded from discretionary-purchase analysis.

More Official record

Director sold ~$78K of Halozyme

Scheduled in advance5d ago